Vera Therapeutics, Inc.
VERA · XNASCIK 1831828fmd_0SH98SQQ08ESGGMKSHVG04QEC3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 45 | 22 | 69 | 78 | 126 | 215 |
| Total operating expenses | 52 | 34 | 91 | 102 | 167 | 315 |
| Operating income | (52) | (34) | (91) | (102) | (167) | (315) |
| Interest expense | 0 | 0 | 1 | 4 | 8 | 8 |
| Interest and investment income | 0 | 0 | 2 | 8 | 21 | 24 |
| Other non-operating income (expense) | (1) | 2 | 2 | 6 | 15 | 16 |
| Income before taxes | (53) | (33) | (89) | (96) | (152) | (300) |
| Income tax expense | (0) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (53) | (33) | (89) | (96) | (152) | (300) |
| Net income | (53) | (33) | (89) | (96) | (152) | (300) |